rebel Financial rebel Financial
← All Posts
CRVS

Corvus Pharmaceuticals, Inc.

June 12, 2026 • Author: Phil Ratcliff • CRVS
Item Proposal Vote
1 To elect two Class I Directors with terms to expire at the 2029 annual meeting of stockholders:
01 Richard A. Miller, M.D. Withhold
02 Linda S. Grais, M.D. J.D ✓ For
2 To ratify the selection of PricewaterhouseCoopers LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2026. ✓ For
3 To approve, on a non-binding advisory basis, the compensation of our named executive officers. ✓ For
Attachments
📄
CRVS_ANNUAL_REPORT_2025.pdf 1.7 MB
📄
CRVS_PROXY_STATEMENT.pdf 0.6 MB
This article was written for information purposes only and its content should not be construed by any consumer and/or prospective client as rebel Financial's solicitation to affect, or attempt to affect transactions in securities, or the rendering of personalized investment advice for compensation. No client or prospective client should assume that any such discussion serves as the receipt of, or a substitute for, personalized advice from rebel Financial, or from any other investment professional. See our disclosures page for more information.